Refining Adjuvant Therapy in HR-Positive/HER2-Negative Early Breast Cancer: Personalizing Care in the CDK4/6 Inhibitor Era

Discover how emerging targeted therapies address systemic drivers in MASLD and MASH. Credit available for this activity expires: 9/8/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/targeting-metabolic-driver-forward-looking-approach-obesity-2026a1000 ...

Are you up to speed on the latest updates on molecular-guided therapies in HR-positive/HER2-negative metastatic breast cancer (MBC)? Join us to learn more. Credit available for this activity expires: 9/18/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewartic ...

Fatigue, unpredictability, and life goals; integrate what patients say they need into how you treat myasthenia gravis (MG). Credit available for this activity expires: 9/4/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/whole-patient-integrating-live ...

Can CAR T-cell therapies achieve drug-free remission in severe refractory autoimmune diseases? Credit available for this activity expires: 9/22/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/patient-journey-severe-refractory-autoimmune-rheumatic-202 ...